BRPI1015559A2 - forma hemi-hidratada, processo para a preparação de um composto, formulação farmacêutica, uso de um composto, método de tratamento de um distúrbio inflamatório, e, produto de combinação. - Google Patents

forma hemi-hidratada, processo para a preparação de um composto, formulação farmacêutica, uso de um composto, método de tratamento de um distúrbio inflamatório, e, produto de combinação.

Info

Publication number
BRPI1015559A2
BRPI1015559A2 BRPI1015559A BRPI1015559A BRPI1015559A2 BR PI1015559 A2 BRPI1015559 A2 BR PI1015559A2 BR PI1015559 A BRPI1015559 A BR PI1015559A BR PI1015559 A BRPI1015559 A BR PI1015559A BR PI1015559 A2 BRPI1015559 A2 BR PI1015559A2
Authority
BR
Brazil
Prior art keywords
compound
treating
preparing
pharmaceutical formulation
inflammatory disorder
Prior art date
Application number
BRPI1015559A
Other languages
English (en)
Inventor
Anett Perlberg
Karol Horvath
Martin Viertelhaus
Ulrika Rosenström
Original Assignee
Cardoz Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cardoz Ab filed Critical Cardoz Ab
Publication of BRPI1015559A2 publication Critical patent/BRPI1015559A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
BRPI1015559A 2009-06-16 2010-06-15 forma hemi-hidratada, processo para a preparação de um composto, formulação farmacêutica, uso de um composto, método de tratamento de um distúrbio inflamatório, e, produto de combinação. BRPI1015559A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18734809P 2009-06-16 2009-06-16
US18735509P 2009-06-16 2009-06-16
PCT/GB2010/001168 WO2010146348A2 (en) 2009-06-16 2010-06-15 New crystalline form of pemirolast

Publications (1)

Publication Number Publication Date
BRPI1015559A2 true BRPI1015559A2 (pt) 2016-04-26

Family

ID=43264726

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1015559A BRPI1015559A2 (pt) 2009-06-16 2010-06-15 forma hemi-hidratada, processo para a preparação de um composto, formulação farmacêutica, uso de um composto, método de tratamento de um distúrbio inflamatório, e, produto de combinação.

Country Status (31)

Country Link
US (3) US20120157415A1 (pt)
EP (2) EP3141549A1 (pt)
JP (2) JP5722317B2 (pt)
KR (2) KR20120032530A (pt)
CN (1) CN102596202B (pt)
AR (1) AR077915A1 (pt)
AU (1) AU2010261540B2 (pt)
BR (1) BRPI1015559A2 (pt)
CA (1) CA2765408A1 (pt)
CY (1) CY1118413T1 (pt)
DK (1) DK2443120T3 (pt)
EA (1) EA025865B1 (pt)
ES (1) ES2613059T3 (pt)
HR (1) HRP20170023T1 (pt)
HU (1) HUE032978T2 (pt)
IL (1) IL216670A (pt)
LT (1) LT2443120T (pt)
ME (1) ME02685B (pt)
MX (1) MX2011013676A (pt)
NZ (1) NZ596747A (pt)
PL (1) PL2443120T3 (pt)
PT (1) PT2443120T (pt)
RS (1) RS55558B1 (pt)
SA (1) SA114350792B1 (pt)
SG (1) SG176295A1 (pt)
SI (1) SI2443120T1 (pt)
SM (1) SMT201700085B (pt)
TW (1) TWI504599B (pt)
UY (1) UY32711A (pt)
WO (2) WO2010146348A2 (pt)
ZA (1) ZA201109045B (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20120115496A (ko) * 2009-11-13 2012-10-18 카르도스 아베 저등급의 전신성 염증을 치료하기 위한 페미로라스트
WO2016063085A1 (en) 2014-10-23 2016-04-28 Rspr Pharma Ab Use of pemirolast in the treatment of acute asthma
WO2016102941A1 (en) 2014-12-22 2016-06-30 Rspr Pharma Ab New combination of pemirolast and montelukast
GB201518831D0 (en) 2015-10-23 2015-12-09 Rspr Pharma Ab New use
KR20190065315A (ko) * 2016-10-03 2019-06-11 브리벤션 파마슈티컬 (상하이) 인크. Trh 아날로그 및 아룬드산을 조합하여 이루어지는 조성물, 그리고 아룬드산의 약학적으로 허용되는 염

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4122274A (en) * 1977-05-25 1978-10-24 Bristol-Myers Company 3-Tetrazolo-5,6,7,8-substituted-pyrido[1,2-a]pyrimidin-4-ones
JP2504788B2 (ja) 1987-11-10 1996-06-05 東京田辺製薬株式会社 ９−メチル−３−（１Ｈ−テトラゾ―ル−５−イル）−４Ｈ−ピリド［１，２−ａ］ピリミジン−４−オンカリウム塩の水性製剤
JP2837449B2 (ja) * 1989-08-11 1998-12-16 東京田辺製薬株式会社 ピリド［１，２―ａ］ピリミジン誘導体の製造法
ITMI20011764A1 (it) 2001-08-10 2003-02-10 Dinamite Dipharma Spa Metodo per l'ottenimento del pemirolast ad elevata purezza
HUE029336T2 (en) 2005-09-16 2017-02-28 Daiichi Sankyo Co Ltd For the preparation of an optically active diamine derivative and process
KR20090106526A (ko) * 2006-12-18 2009-10-09 카르도스 아베 염증 질환 치료를 위한 새로운 조합
US20100168137A1 (en) * 2006-12-20 2010-07-01 Johan Raud Combination for use in the treatment of inflammatory disorders

Also Published As

Publication number Publication date
DK2443120T3 (en) 2017-01-09
ZA201109045B (en) 2013-05-29
CN102596202A (zh) 2012-07-18
TW201100422A (en) 2011-01-01
US20140329839A1 (en) 2014-11-06
SG176295A1 (en) 2012-01-30
IL216670A0 (en) 2012-02-29
AU2010261540A2 (en) 2012-01-19
CA2765408A1 (en) 2010-12-23
PL2443120T3 (pl) 2017-04-28
HUE032978T2 (hu) 2017-11-28
EA201200017A1 (ru) 2013-10-30
WO2010146341A2 (en) 2010-12-23
KR20170049645A (ko) 2017-05-10
EP2443120A2 (en) 2012-04-25
EP3141549A1 (en) 2017-03-15
JP2012530118A (ja) 2012-11-29
US9006431B2 (en) 2015-04-14
PT2443120T (pt) 2017-02-08
US20170202839A1 (en) 2017-07-20
UY32711A (es) 2011-01-31
US20120157415A1 (en) 2012-06-21
WO2010146348A3 (en) 2011-03-03
ES2613059T3 (es) 2017-05-22
LT2443120T (lt) 2017-02-10
TWI504599B (zh) 2015-10-21
NZ596747A (en) 2014-01-31
ME02685B (me) 2017-06-20
AU2010261540A1 (en) 2012-01-19
IL216670A (en) 2017-02-28
HRP20170023T1 (hr) 2017-03-10
KR20120032530A (ko) 2012-04-05
AU2010261540B2 (en) 2016-04-14
WO2010146348A2 (en) 2010-12-23
JP5722317B2 (ja) 2015-05-20
SMT201700085B (it) 2017-03-08
CN102596202B (zh) 2015-01-21
SA114350792B1 (ar) 2015-11-10
SI2443120T1 (sl) 2017-04-26
WO2010146348A9 (en) 2012-05-03
RS55558B1 (sr) 2017-05-31
MX2011013676A (es) 2012-02-08
EP2443120B1 (en) 2016-11-02
EA025865B1 (ru) 2017-02-28
WO2010146341A3 (en) 2011-03-03
CY1118413T1 (el) 2017-06-28
AR077915A1 (es) 2011-10-05
JP2015120750A (ja) 2015-07-02

Similar Documents

Publication Publication Date Title
BR112012026570A2 (pt) composto, composição farmacêutica, uso de um composto, método para o tratamento de um indíviduo e produto combinado
BRPI1010937A2 (pt) composto, uso de um composto, e, método para tratar câncer
BR112014003681A8 (pt) composto, composição farmacêutica, produto de combinação farmacêutica, uso de um composto, e, método para tratar doenças ou condições
BR112013030163A2 (pt) composto, uso cosmético de pelo menos um composto, composição farmacêutica ou cosmética e processo para preparar um composto.
BR112014010460A2 (pt) composto, composição farmacêutica, processo para produzir uma composição farmacêutica, método de tratamento, kit e uso de uma composição farmacêutica
BR112014010206A2 (pt) composto, composição farmacêutica, uso de composto, e, método para a profilaxia ou tratamento de um estado ou condição de doença
BR112014010179A8 (pt) composto, composição farmacêutica, uso de um composto, e, método para a profilaxia ou tratamento de um estado ou condição
BR112012026843A2 (pt) composição, composição farmacêutica, processo para preparar uma composição farmacêutica, uso de uma composição e método para tratamento de hiv
BRPI0922475A2 (pt) composto, composição farmacêutica , método para tratar câncer, e, uso de um composto.
BR112013009486A2 (pt) processo para preparação de formas de dosagem gastrirretentivas multiparticuladas
BRPI0919488A2 (pt) composto, uso de um composto, método para tratar câncer em um animal de sangue quente, composição farmacêutica, e, processo para preparar um composto
BR112013020611A2 (pt) método para produção de compostos quelato de aminoácido, compostos quelato de aminoácido e uso de compostos quelato de aminoácido
BRPI0909198A2 (pt) composto antifolato, composto, método para preparar um composto antifolato, composição farmacêutica, método para tratar
BRPI1012651A2 (pt) processo para produzir preparações de substâncias fracamente solúveis em água
BRPI0908252A2 (pt) Processo para preparar um composto, e, uso de um composto
BRPI1010933A2 (pt) processo para a preparação de um pó, e, composto
BRPI1013396A2 (pt) composto, produto farmacêutico de combinação, uso de um composto, método para tratar uma doença ou condição, e, processo para a preparação de um composto.
BRPI0915856A2 (pt) processo para preparar micropartículas, uso de um auxiliar de processamento, micropartículas, e, composição
BR112013008008A2 (pt) composto, composição farmacêutica e processo para preparar um composto
BR112014013354A2 (pt) processo para a preparação de um polímero, composição, composto, e, formulação
BRPI0925100A2 (pt) forma de dosagem osmótica e processo para preparar uma forma de dosagem osmótica
BR112014009684A2 (pt) processo para preparar polímeros, polímero e uso de polímeros
BRPI1014691A2 (pt) Composto, e, processo para a preparação de um composto.
BR112013018942A2 (pt) processo para o preparo de 4-amino-3-cloro-5-fluro-6(substituído) picolinatos.
BR112014006910A2 (pt) composto, substância farmacêutica do composto, método para produzir a substância farmacêutica, uso da substância farmacêutica, método de ensaio de titulação, e, composição farmacêutica e parafarmacêutica

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]